Photo by santoelia/iStock via Getty Images
“Perseverance, secret of all triumphs.”― Victor Hugo
Today, we circle back on PhaseBio (NASDAQ:PHAS) for the first time since we penned an article on this ‘Tier 4’ developmental concern late in 2019. The company recently did a capital raise, and not surprisingly also has seen an uptick of positive analyst coverage over the past couple of months. It seems an appropriate time to revisit this small-cap concern. A full analysis follows below.